SC
CAI icon

SummitTX Capital’s Caris Life Sciences CAI Stock Holding History

SummitTX Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,736
Closed -$204K – 1016
2025
Q3 		$204K Buy
+6,736
New +$215K 0.01% 702

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SummitTX Capital's CAI Position: Q4 2025 in Review

SummitTX Capital sold out of Caris Life Sciences (CAI) in Q4 2025, closing a stake of 6,736 shares — an estimated $204K sold.

SummitTX Capital first reported a position in CAI in Q3 2025 and held it in 1 quarter. The position peaked at $204K in Q3 2025. 186 funds tracked by Wall St. Rank hold CAI as of Q4 2025.

  • SummitTX Capital reported no remaining Caris Life Sciences position as of Q4 2025 after selling out during the quarter.
  • SummitTX Capital sold 6,736 Caris Life Sciences shares in Q4 2025, an estimated $204K.
  • SummitTX Capital first reported a position in Caris Life Sciences in Q3 2025 and held it in 1 quarter.
  • SummitTX Capital's Caris Life Sciences position peaked at $204K in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Caris Life Sciences as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.